In ovarian cancer, bevacizumab (anti-VEGF receptor 2 (VEGFR2) monoclonal antibody) is one of the few targeted therapies available for patients, inhibiting the binding of VEGF to its receptor and, therefore, regulating and normalizing the blood vessels [20,21]. The gene discussed is VEGFA; the disease is ovarian carcinoma.